» Articles » PMID: 38571851

Implications of Gender on the Outcome in Patients With Autoimmune Hepatitis

Overview
Journal Cureus
Date 2024 Apr 4
PMID 38571851
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Autoimmune hepatitis (AIH) is uncommon and predominantly affects females. Data on AIH from India are scanty. We retrospectively analyzed the spectrum and outcome of adults with AIH and compared it between male and female patients.

Methods: AIH was diagnosed using a simplified AIH score. For suspected seronegative AIH, the revised score was used. Standard therapies for AIH and portal hypertension were administered and response was assessed at six months. Relapse rates and five-year mortality were also evaluated.

Results: Of the 157 patients with AIH, 85 (male: female 25: 60) were included in the study. The median age at diagnosis was 46 (interquartile range (IQR) 32-55.5) years in males vs 45 (IQR 34.2-54) years in females (p=0.91). A similar proportion of male and female patients presented with cirrhosis, acute severe AIH, or AIH-related acute on chronic liver failure (ACLF); Extra-hepatic autoimmune diseases were less common in male patients (16% vs 35.5% p=0.02). Other laboratory and histological features were comparable in both groups. During the median follow-up period of 51 months (IQR 45-67 months). The biochemical and clinical response at six months were seen in 64% of male patients and 63.3% of female patients (p= 0.57). Of patients, 75% relapsed in the male AIH group (12 of 16 patients) after initial remission compared to 42% in the female group (p=0.02). Five-year mortality was 14.1%, and no patient developed hepatocellular carcinoma.

Conclusion: Male and female patients with AIH have similar clinical, biochemical, and histological profiles. More male patients relapsed after an initial response to therapy.

Citing Articles

Acute Hepatitis E Virus Infection Triggering Autoimmune Hepatitis in a Patient With Chronic Liver Disease: Case Report and the Review of the Literature.

Malakar S, Shah N, Mishra A, Pandey V, Shirol V, Wodeyar N Cureus. 2024; 16(3):e56344.

PMID: 38633970 PMC: 11021215. DOI: 10.7759/cureus.56344.

References
1.
Colapietro F, Maisonneuve P, Lytvyak E, Beuers U, Verdonk R, van der Meer A . Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis. J Hepatol. 2023; 80(1):53-61. DOI: 10.1016/j.jhep.2023.09.010. View

2.
Montano-Loza A, Carpenter H, Czaja A . Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology. 2007; 46(4):1138-45. DOI: 10.1002/hep.21787. View

3.
Mack C, Adams D, Assis D, Kerkar N, Manns M, Mayo M . Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2019; 72(2):671-722. DOI: 10.1002/hep.31065. View

4.
Taneja S, Mehtani R, De A, Mitra S, Rathi S, Verma N . Spectrum of Autoimmune Liver Disease and Real-World Treatment Experience from a Tertiary Care Hospital. J Clin Exp Hepatol. 2023; 13(2):241-251. PMC: 10025584. DOI: 10.1016/j.jceh.2022.11.002. View

5.
Stravitz R, Lefkowitch J, Fontana R, Gershwin M, Leung P, Sterling R . Autoimmune acute liver failure: proposed clinical and histological criteria. Hepatology. 2011; 53(2):517-26. PMC: 3080034. DOI: 10.1002/hep.24080. View